Skip to content

A Study of Axiron® in Healthy Participants

A Phase 1, Single-Dose Study to Evaluate Testosterone on Clothing After Axiron® Use in Healthy Male Subjects

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02004132
Enrollment
12
Registered
2013-12-06
Start date
2013-12-31
Completion date
2013-12-31
Last updated
2014-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Brief summary

The study involves application of Axiron to each underarm. The study will evaluate the transfer of testosterone from underarms to the clothing items that the participant is wearing and other fabric items washed with participant's' clothes. The study is approximately 6 days, not including screening. Screening is required within 28 days prior to the start of the study.

Interventions

DRUGAxiron

Solution administered topically using pump and applicator

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Are overtly healthy males, as determined by medical history and physical examination, or males who have been on stable medication for at least 1 month and have no significant clinical conditions. * Agree to use a reliable method of birth control (for example: condom or vasectomy) during the study and for 3 months following the Axiron dose * Have clinical laboratory test results within the normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator * Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures * Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site

Exclusion criteria

* Are currently enrolled in a clinical trial involving an investigational product or off-label use of a drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study * Are participants who have previously completed or withdrawn from this study or any other study investigating Axiron in the past 3 months * Have known allergies to testosterone solution, related compounds, or any components of the formulation, or history of significant atopy * Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study * Have an abnormal blood pressure as determined by the investigator * Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders constituting a risk when taking the study medication or that could interfere with the interpretation of the data * Have had lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years * Regularly use known drugs of abuse and/or show positive findings on urinary drug screening * Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies * Show evidence of hepatitis C and/or positive hepatitis C antibody * Show evidence of hepatitis B and/or positive hepatitis B surface antigen * Use of any topical testosterone replacement therapy within the 3 months prior to study entry through study discharge, except for use of Axiron as directed by study procedures * Use of parenteral testosterone replacement (testosterone enthanate, testosterone cypionate) within the 30 days prior to screening. Use of long acting intramuscular testosterone undecanoate 6 months prior to screening, or use of testosterone pellets 12 months prior to screening * Have a dermatologic condition in the underarm area that might be exacerbated by topical testosterone replacement therapy, in the opinion of the investigator * In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study

Design outcomes

Primary

MeasureTime frameDescription
Amount of Testosterone on T-shirts12 hours after application of study drugThis is a summary of the amounts of testosterone measured on a 10 centimeters (cm) × 10 cm of material excised from the underarm area of participant's unwashed t-shirt halves.

Secondary

MeasureTime frameDescription
Amount of Testosterone Following Laundering12 hours after application of study drugThis is a summary of the amounts of testosterone measured on a 10 cm × 10 cm of material excised from the underarm area of washed t-shirt halves following laundering in a standard washing machine.
Amount of Testosterone on Unworn Textiles Laundered With the Testosterone Exposed T-shirts12 hours after application of study drugThis is a summary of the amounts of testosterone measured on unworn textile items washed with t-shirt halves exposed to testosterone in a standard washing machine. Total amounts of testosterone on each laundered item other than the t-shirt halves was calculated based on the weight of the fabric sample analyzed and the total weight of the item, assuming a uniform distribution of testosterone across each item as: (weight of laundered item / weight of laundered sample) x amount of testosterone on laundered sample.

Countries

United States

Participant flow

Participants by arm

ArmCount
Axiron 120 mg
Single 120 milligrams (mg) total dose given to participants as two 1.5 milliliters (mL) topical applications to each underarm (60 mg per underarm) in the morning on Day 1 using a pump.
12
Total12

Baseline characteristics

CharacteristicAxiron 120 mg
Age, Continuous38.3 years
STANDARD_DEVIATION 10.6
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
5 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
6 Participants
Region of Enrollment
United States
12 participants
Sex: Female, Male
Female
0 Participants
Sex: Female, Male
Male
12 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
2 / 12
serious
Total, serious adverse events
0 / 12

Outcome results

Primary

Amount of Testosterone on T-shirts

This is a summary of the amounts of testosterone measured on a 10 centimeters (cm) × 10 cm of material excised from the underarm area of participant's unwashed t-shirt halves.

Time frame: 12 hours after application of study drug

Population: Full analysis set (FAS). Data from all enrolled participants completing the study.

ArmMeasureValue (MEAN)Dispersion
Axiron 120 mgAmount of Testosterone on T-shirts7603 micrograms (µg)Standard Deviation 2790
Secondary

Amount of Testosterone Following Laundering

This is a summary of the amounts of testosterone measured on a 10 cm × 10 cm of material excised from the underarm area of washed t-shirt halves following laundering in a standard washing machine.

Time frame: 12 hours after application of study drug

Population: FAS. Data from all enrolled participants completing the study.

ArmMeasureValue (MEAN)Dispersion
Axiron 120 mgAmount of Testosterone Following Laundering260 µgStandard Deviation 407
Secondary

Amount of Testosterone on Unworn Textiles Laundered With the Testosterone Exposed T-shirts

This is a summary of the amounts of testosterone measured on unworn textile items washed with t-shirt halves exposed to testosterone in a standard washing machine. Total amounts of testosterone on each laundered item other than the t-shirt halves was calculated based on the weight of the fabric sample analyzed and the total weight of the item, assuming a uniform distribution of testosterone across each item as: (weight of laundered item / weight of laundered sample) x amount of testosterone on laundered sample.

Time frame: 12 hours after application of study drug

Population: FAS. Data from all enrolled participants completing the study.

ArmMeasureGroupValue (MEAN)Dispersion
Axiron 120 mgAmount of Testosterone on Unworn Textiles Laundered With the Testosterone Exposed T-shirtsBleached Cotton Terry Cloth308 µgStandard Deviation 71.9
Axiron 120 mgAmount of Testosterone on Unworn Textiles Laundered With the Testosterone Exposed T-shirtsWool Jersey Knit Fabric122 µgStandard Deviation 23.8
Axiron 120 mgAmount of Testosterone on Unworn Textiles Laundered With the Testosterone Exposed T-shirts56/44 Cotton/Linen441 µgStandard Deviation 70.8
Axiron 120 mgAmount of Testosterone on Unworn Textiles Laundered With the Testosterone Exposed T-shirtsTexturized Dacron 56T Double68.7 µgStandard Deviation 21
Axiron 120 mgAmount of Testosterone on Unworn Textiles Laundered With the Testosterone Exposed T-shirts87/13 Nylon/Lycra Knit10402 µgStandard Deviation 1408

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026